Orchid Pharma has released its monitoring agency report for the quarter ended March 31, 2026, detailing the utilization of proceeds from its ₹400 crore Qualified Institutional Placement (QIP). The report confirms that there have been no deviations from the company’s stated project objects. While progress continues, the company noted a significant delay in the Jammu manufacturing facility project, with commercial operations now anticipated to commence by February 2027.
Utilization of QIP Proceeds
As of March 31, 2026, Orchid Pharma has maintained transparency regarding the allocation of funds raised through its QIP. The company successfully reallocated proceeds following shareholder approval obtained during the Annual General Meeting on September 20, 2025. This strategic adjustment prioritized investment in the Orchid Bio Pharma Limited manufacturing facility in Jammu and debt repayment, while scaling back the allocation for the API facility in Alathur, Tamil Nadu.
Project Updates and Facility Progress
The company provided key updates on its major capital projects:
- Alathur API Facility: Capital expenditure requirements for the new block have been fully utilized as of June 2025, with no further investment expected from QIP proceeds.
- Jammu Manufacturing Facility: The project is currently experiencing delays due to the land acquisition process, which is being handled by a land aggregator. The construction of the major building is currently in an advanced stage, and the installation of equipment has commenced.
Outlook and Timeline
Due to the aforementioned land acquisition complexities, the timeline for the Jammu facility has been revised. Management now expects commercial operations to begin by February 2027. The company remains committed to its revised deployment schedule, ensuring that all remaining funds are managed in accordance with the updated project priorities approved by the board.
Source: BSE
